A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects With Albuminuria and an eGFR ≥30-<60 mL/Min/1.73m^2
1 other identifier
interventional
49
6 countries
50
Brief Summary
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Dec 2012
50 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2012
CompletedFirst Submitted
Initial submission to the registry
December 20, 2012
CompletedFirst Posted
Study publicly available on registry
December 27, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2014
CompletedFebruary 9, 2015
February 1, 2015
1.8 years
December 20, 2012
February 5, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Percentage change from baseline in Urine albumin-to-creatinine ratio (UACR) within group.
up to 8 weeks
Frequency and nature of treatment-emergent adverse events and serious adverse events.
up to 16 weeks
Secondary Outcomes (3)
Percentage change from baseline in UACR compared to placebo
up to 8 weeks
Change from baseline in Systolic Blood Pressure and Diastolic Blood Pressure within group.
up to 8 weeks
Plasma concentrations of MT-3995 and its major metabolite
up to 16 weeks
Study Arms (3)
MT-3995 Low group
EXPERIMENTALMT-3995 High group
EXPERIMENTALPlacebo group
PLACEBO COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Subjects with Type II diabetic nephropathy, who have been treated with angiotensin converting enzyme-inhibitor (ACE-I) or angiotensin II receptor blocker (ARB)
- Glycosylated haemoglobin (HbA1c) ≤10.5%
- An estimated glomerular filtration rate (eGFR) ≥30-\<60 mL/min/1.73m\^2
- Subject with albuminuria
You may not qualify if:
- History of Type I diabetes, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
- Serum potassium level \<3.5 or \>5.0 mmol/L
- Subjects who had acute kidney injury (AKI) within 3 months prior to baseline or have undergone renal dialysis at any time prior to randomisation
- Subjects with a history of renal transplant
- Subjects with clinically significant hypotension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (50)
Investigational site
Blagoevgrad, Bulgaria
Investigational site
Pazardzhik, Bulgaria
Investigational site
Pleven, Bulgaria
Investigational site
Plovdiv, Bulgaria
Investigational site
Rousse, Bulgaria
Investigational site
Sofia, Bulgaria
Investigational site
Varna, Bulgaria
Investigational site
České Budějovice, Czechia
Investigational site
Český Krumlov, Czechia
Investigational site
Karlovy Vary, Czechia
Investigational site
Ostrava, Czechia
Investigational site
Ostrava-Vitkovice, Czechia
Investigational site
Prague, Czechia
Investigational site
Slaný, Czechia
Investigational site
Znojmo, Czechia
Investigational site
Baja, Hungary
Investigational site
Budapest, Hungary
Investigational site
Debrecen, Hungary
Investigational site
Eger, Hungary
Investigational site
Kistelek, Hungary
Investigational site
Komárom, Hungary
Investigational site
Pécs, Hungary
Investigational site
Szigetvár, Hungary
Investigational site
Szikszó, Hungary
Investigational site
Zalaegerszeg, Hungary
Investigational site
Krakow, Poland
Investigational site
Ruda Śląska, Poland
Investigational site
Rzeszów, Poland
Investigational site
Świętochłowice, Poland
Investigational site
Bacau, Romania
Investigational site
Brăila, Romania
Investigational site
Bucharest, Romania
Investigational site
Buzău, Romania
Investigational site
Cluj-Napoca, Romania
Investigational site
Deva, Romania
Investigational site
Iași, Romania
Investigational site
Oradea, Romania
Investigational site
Ploiesti, Judet Prahova, Romania
Investigational site
Satu Mare, Romania
Investigational site
Târgu Mureş, Romania
Investigational site
Timișoara, Romania
Investigational site
Bardejov, Slovakia
Investigational site
Bratislava, Slovakia
Investigational site
Levice, Slovakia
Investigational site
Lučenec, Slovakia
Investigational site
Martin, Slovakia
Investigational site
Nitra, Slovakia
Investigational site
Prešov, Slovakia
Investigational site
Šahy, Slovakia
Investigational site
Štúrovo, Slovakia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 20, 2012
First Posted
December 27, 2012
Study Start
December 1, 2012
Primary Completion
September 1, 2014
Study Completion
September 1, 2014
Last Updated
February 9, 2015
Record last verified: 2015-02